Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963375 | 0.83 | TAAR1 (0.58) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| Amphetamine SCHEMBL41204 | 0.82 | TAAR1 (0.76) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| Amphetamine SCHEMBL6465998 | 0.82 | TAAR1 (0.76) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| Amphetamine SCHEMBL2412146 | 0.82 | TAAR1 (0.76) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| Dextroamphetamine SCHEMBL7204032 | 0.82 | TAAR1 (0.76) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| Amphetamine SCHEMBL8025793 | 0.82 | TAAR1 (0.76) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| Amphetamine SCHEMBL4016537 | 0.82 | TAAR1 (0.76) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| Dextroamphetamine SCHEMBL18948 | 0.82 | TAAR1 (0.76) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| Amphetamine SCHEMBL41203 | 0.82 | TAAR1 (0.76) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 | |
| Levamfetamine SCHEMBL396231 | 0.82 | TAAR1 (0.76) | TAAR1SLC6A2SIGMAR1MAOASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2478981-B1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | SUMITOMO CHEMICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| US-9704612-B2 | Composition of silver-conjugated compound composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-07-11 | — | — | US | disclosed |
| US-9412487-B2 | Silver-(conjugated compound) composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-09 | — | — | US | disclosed |
| US-8871720-B2 | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus | SEATTLE GENETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140001422-A1 | COMPOSITION OF SILVER-CONJUGATED COMPOUND COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-02 | — | — | US | disclosed |
| EP-2478981-A1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | Sumitomo Chemical Co., Ltd (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120168693-A1 | SILVER-(CONJUGATED COMPOUND) COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20090111756-A1 | Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus | SEATTLE GENECTICS, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| US-6737544-B1 | HEATING ABOVE MELTING POINT | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-18 | — | — | US | disclosed |
| EP-0998468-A1 | SUBSTITUTED 3-PHENYL ISOXAZOLINES | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-10 | — | — | EP | disclosed |
| WO-2000023413-A1 | METHOD FOR DRYING PHENOXYMETHYLBENZOIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-27 | — | — | WO | disclosed |
| EP-0971904-A1 | NOVEL 1-AMINO-3 BENZYL URACILS | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1999005130-A1 | SUBSTITUTED 3-PHENYL ISOXAZOLINES | BASF AKTIENGESELLSCHAFT (DE) | 1999-02-04 | — | — | WO | disclosed |
| EP-0891336-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-20 | — | — | EP | disclosed |
| WO-1998042682-A1 | NOVEL 1-AMINO-3 BENZYL URACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-01 | — | — | WO | disclosed |
| CN-1189824-A | 1-amino-3-benzyluracils | BASF AG (DE) | 1998-08-05 | — | — | CN | disclosed |
| EP-0835248-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997035845-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997001543-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111756-A1 | Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus | MMAB, PTMS, CAD | TAAR1 4232/4885SLC6A2 3095/4885SIGMAR1 4387/4885 |
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | CBR1, CBR3, QSOX1 | TAAR1 1548/4885SLC6A2 4298/4885SIGMAR1 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.